🔴 Nasus Pharma is trading 8.6% down today after CFO Eyal Rubin announces departure

Nasus Pharma is trading 8.59% down now at $3.51 after announcing on August 19, 2026, that CFO Eyal Rubin will leave for an opportunity outside the life-science industry.

• Rubin will remain through September 18; Director of Finance Oren Elmaliach becomes interim CFO.
• The leadership change appears to be the primary catalyst, with broader market weakness adding pressure during the August 20 session.
• Nasus Pharma gained 5.21% on August 19 and 13.12% on August 14, making today’s decline a sharp reversal.